Dataset Information

Epileptic seizures triggered by eating in dogs.

ABSTRACT:

Background

Seizures triggered by eating (STE) behavior are very rare in humans and have not been documented previously in dogs.

Objectives

To document the occurrence of STE in dogs and describe their clinical features.

Animals

Ten client-owned dogs with STE diagnosed at 5 European referral centers.

Methods

A call for suspected cases of STE was made online. This call was followed by a retrospective review of medical records, combined with a questionnaire to be completed by both the owner and the board-certified neurologist who made the diagnosis. Cases were included if >50% of the seizures that occurred were related to eating and if a minimum diagnostic evaluation for seizures had been performed.

Results

Four cases only had STE and 6 cases had both STE and spontaneous seizures. Four of the dogs were retrievers. The most common seizure type was focal epileptic seizures evolving to become generalized. Nine dogs were diagnosed with idiopathic epilepsy. One dog had a presumptive diagnosis of glioma involving the margins of the parietal, temporal, and frontal cortex (the perisylvian region), an area known to have a key role in eating-associated epilepsy in people. Treatment strategies included a combination of pharmacological management and eating habit changes.

Conclusions and clinical importance

We have identified a form of reflex epilepsy in dogs, with STE behavior. Further studies are warranted to improve the characterization and management of STE.

SUBMITTER: Brocal J

PROVIDER: S-EPMC7255664 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Epileptic seizures triggered by eating in dogs.

Brocal Josep J Lowrie Mark M Wamsley Gemma G Cauduro Alberto A Mandigers Paul P Gutierrez-Quintana Rodrigo R Stalin Catherine C

Journal of veterinary internal medicine 20200428 3

<h4>Background</h4>Seizures triggered by eating (STE) behavior are very rare in humans and have not been documented previously in dogs.<h4>Objectives</h4>To document the occurrence of STE in dogs and describe their clinical features.<h4>Animals</h4>Ten client-owned dogs with STE diagnosed at 5 European referral centers.<h4>Methods</h4>A call for suspected cases of STE was made online. This call was followed by a retrospective review of medical records, combined with a questionnaire to be complet ...[more]

PMID: 32343869

Similar Datasets

Project description:The use of cannabidiol (CBD) in childhood refractory seizures has become a common therapeutic approach for specific seizure disorders in human medicine. Similarly, there is an interest in using CBD, cannabidiolic acid (CBDA) or cannabinoid-rich hemp products in the treatment of idiopathic epilepsy in dogs. We aimed to examine a small cohort in a pilot investigation using a CBD and CBDA-rich hemp product for the treatment of refractory epileptic seizures in dogs. Fourteen dogs were examined in a 24-week randomized cross-over study being provided placebo or CBD/CBDA-rich hemp extract treatment at 2 mg/kg orally every 12 h for each 12-week arm of the study. Serum chemistry, complete blood counts, serum anti-seizure medication (ASM) concentrations and epileptic seizure frequency were followed over both arms of the cross-over trial. Results demonstrated that besides a mild increase in alkaline phosphatase, there were no alterations observed on routine bloodwork at 2, 6, and 12 weeks during either arm of the study. Epileptic seizure frequency decreased across the population from a mean of 8.0 ± 4.8 during placebo treatment to 5.0 ± 3.6 with CBD/CBDA-rich hemp extract (P = 0.02). In addition, epileptic seizure event days over the 12 weeks of CBD/CBDA-rich hemp treatment were 4.1 ± 3.4, which was significantly different than during the 12 weeks of placebo treatment (5.8 ± 3.1; P =0.02). The number of dogs with a 50% reduction in epileptic activity while on treatment were 6/14, whereas 0/14 had reductions of 50% or greater while on the placebo (P = 0.02). No differences were observed in serum zonisamide, phenobarbital or bromide concentrations while on the treatment across groups. Adverse events were minimal, but included somnolence (3/14) and transient increases in ataxia (4/14) during CBD/CBDA-rich hemp extract treatment; this was not significantly different from placebo. This further indicates that providing CBD/CBDA-rich hemp extract during refractory epilepsy (only partially responsive to ASM), in conjunction with other ASM appears safe. Based on this information, the use of 2 mg/kg every 12 h of a CBD/CBDA-rich hemp extract can have benefits in reducing the incidence of epileptic seizures, when used concurrently with other ASMs.

Dataset Information

Epileptic seizures triggered by eating in dogs.

Background

Objectives

Animals

Methods

Results

Conclusions and clinical importance

Publications

Epileptic seizures triggered by eating in dogs.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets